Entolimod is under clinical development by Statera Biopharma and currently in Phase I for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). According to GlobalData, Phase I drugs for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Entolimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Entolimod overview
Entolimod (CBLB-502) is under development for the treatment of acute radiation syndrome, unspecified cancer, acute and chronic neutropenia and anemia. The drug candidate is administered through intramuscular and subcutaneous routes. The drug candidate is a recombinant derivative of the bacterial protein flagellin that acts by targeting toll-like receptor 5 (TLR5). The drug candidate was also under development for the treatment of liver metastasis, squamous cell carcinoma of the nasopharynx, oropharynx, oral cavity, paranasal sinuses, larynx, hypopharynx and head and neck cancer squamous cell carcinoma. It is being developed based on AIMS: Advanced Immunomodulating Multi-receptor System platform.
It was also under development for the treatment of colorectal cancer, uveal melanoma, non-small cell lung cancer, anal cancer and urothelial bladder cancer.
Statera Biopharma overview
Statera Biopharma, formerly Cytocom Inc, is a clinical-stage biopharmaceutical company that developing novel immunotherapies targeting autoimmune, neutropenia and anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body鈥檚 immune system and restore homeostasis. The company鈥檚 clinical program includes STAT-201, STAT-401 and STAT-205 for the treatment of crohn鈥檚 disease, hematology (entolimod), pancreatic cancer and covid-19. Statera Biopharma has a large platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists and the TLR5 agonists, entolimod and GP532. The company operates in the US and Russia. Statera Biopharma is headquartered in Buffalo, New York, the US.
For a complete picture of Entolimod’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
